Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma … Read more
Celltrion Inc (068270) - Net Assets
Latest net assets as of September 2025: ₩16.84 Trillion KRW
Based on the latest financial reports, Celltrion Inc (068270) has net assets worth ₩16.84 Trillion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩21.08 Trillion) and total liabilities (₩4.24 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩16.84 Trillion |
| % of Total Assets | 79.89% |
| Annual Growth Rate | 46.51% |
| 5-Year Change | 412.9% |
| 10-Year Change | 871.36% |
| Growth Volatility | 177.25 |
Celltrion Inc - Net Assets Trend (2007–2024)
This chart illustrates how Celltrion Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Celltrion Inc (2007–2024)
The table below shows the annual net assets of Celltrion Inc from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩17.58 Trillion | +2.65% |
| 2023-12-31 | ₩17.13 Trillion | +300.68% |
| 2022-12-31 | ₩4.27 Trillion | +5.53% |
| 2021-12-31 | ₩4.05 Trillion | +18.17% |
| 2020-12-31 | ₩3.43 Trillion | +19.31% |
| 2019-12-31 | ₩2.87 Trillion | +10.70% |
| 2018-12-31 | ₩2.60 Trillion | +7.66% |
| 2017-12-31 | ₩2.41 Trillion | +9.62% |
| 2016-12-31 | ₩2.20 Trillion | +21.50% |
| 2015-12-31 | ₩1.81 Trillion | +34.28% |
| 2014-12-31 | ₩1.35 Trillion | +23.98% |
| 2013-12-31 | ₩1.09 Trillion | +3.52% |
| 2012-12-31 | ₩1.05 Trillion | +16.74% |
| 2011-12-31 | ₩899.55 Billion | +15.34% |
| 2010-12-31 | ₩779.89 Billion | +173.00% |
| 2009-12-31 | ₩285.67 Billion | +30.02% |
| 2008-12-31 | ₩219.72 Billion | +726.32% |
| 2007-12-31 | ₩26.59 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Celltrion Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27689.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩3.74 Trillion | 21.47% |
| Other Components | ₩13.69 Trillion | 78.53% |
| Total Equity | ₩17.44 Trillion | 100.00% |
Celltrion Inc Competitors by Market Cap
The table below lists competitors of Celltrion Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coca-Cola European Partners PLC
NASDAQ:CCEP
|
$19.26 Billion |
|
Anhui Conch Cement Co Ltd
PINK:AHCHY
|
$19.28 Billion |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
$19.31 Billion |
|
WuXi AppTec Co. Ltd
PINK:WUXIF
|
$19.34 Billion |
|
Telus Corp
NYSE:TU
|
$19.23 Billion |
|
NetApp Inc
NASDAQ:NTAP
|
$19.22 Billion |
|
Bank Central Asia Tbk
JK:BBCA
|
$19.22 Billion |
|
Li Auto Inc
NASDAQ:LI
|
$19.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celltrion Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 16,980,683,406,960 to 17,439,141,579,250, a change of 458,458,172,290 (2.7%).
- Net income of 422,691,724,150 contributed positively to equity growth.
- Dividend payments of 103,604,041,760 reduced retained earnings.
- Share repurchases of 438,816,707,860 reduced equity.
- New share issuances of 21,129,774,460 increased equity.
- Other factors increased equity by 557,057,423,300.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩422.69 Billion | +2.42% |
| Dividends Paid | ₩103.60 Billion | -0.59% |
| Share Repurchases | ₩438.82 Billion | -2.52% |
| Share Issuances | ₩21.13 Billion | +0.12% |
| Other Changes | ₩557.06 Billion | +3.19% |
| Total Change | ₩- | 2.70% |
Book Value vs Market Value Analysis
This analysis compares Celltrion Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 53.53x to 2.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | ₩3618.76 | ₩193700.00 | x |
| 2008-12-31 | ₩1833.60 | ₩193700.00 | x |
| 2009-12-31 | ₩2320.23 | ₩193700.00 | x |
| 2010-12-31 | ₩5872.06 | ₩193700.00 | x |
| 2011-12-31 | ₩6464.62 | ₩193700.00 | x |
| 2012-12-31 | ₩15241.17 | ₩193700.00 | x |
| 2013-12-31 | ₩7976.31 | ₩193700.00 | x |
| 2014-12-31 | ₩9153.69 | ₩193700.00 | x |
| 2015-12-31 | ₩12063.28 | ₩193700.00 | x |
| 2016-12-31 | ₩14176.19 | ₩193700.00 | x |
| 2017-12-31 | ₩15755.07 | ₩193700.00 | x |
| 2018-12-31 | ₩17054.25 | ₩193700.00 | x |
| 2019-12-31 | ₩19015.39 | ₩193700.00 | x |
| 2020-12-31 | ₩22740.16 | ₩193700.00 | x |
| 2021-12-31 | ₩26916.89 | ₩193700.00 | x |
| 2022-12-31 | ₩29926.22 | ₩193700.00 | x |
| 2023-12-31 | ₩81904.76 | ₩193700.00 | x |
| 2024-12-31 | ₩81039.61 | ₩193700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celltrion Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.88%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.21x
- Recent ROE (2.42%) is below the historical average (11.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 9.04% | 3.81% | 0.98x | 2.43x | ₩-243.54 Million |
| 2008 | 6.63% | 17.41% | 0.17x | 2.27x | ₩-7.40 Billion |
| 2009 | 20.49% | 40.22% | 0.26x | 1.96x | ₩29.98 Billion |
| 2010 | 13.90% | 59.89% | 0.16x | 1.48x | ₩30.38 Billion |
| 2011 | 18.65% | 60.14% | 0.20x | 1.56x | ₩77.85 Billion |
| 2012 | 16.61% | 49.81% | 0.20x | 1.65x | ₩69.42 Billion |
| 2013 | 9.42% | 45.29% | 0.11x | 1.82x | ₩-6.26 Billion |
| 2014 | 9.03% | 23.92% | 0.20x | 1.86x | ₩-12.06 Billion |
| 2015 | 9.09% | 25.54% | 0.22x | 1.62x | ₩-15.33 Billion |
| 2016 | 8.67% | 26.54% | 0.22x | 1.47x | ₩-27.37 Billion |
| 2017 | 16.10% | 38.80% | 0.29x | 1.44x | ₩139.48 Billion |
| 2018 | 9.88% | 25.02% | 0.28x | 1.41x | ₩-2.90 Billion |
| 2019 | 10.91% | 26.68% | 0.29x | 1.40x | ₩25.02 Billion |
| 2020 | 15.65% | 28.00% | 0.37x | 1.52x | ₩186.99 Billion |
| 2021 | 14.79% | 30.31% | 0.34x | 1.45x | ₩187.74 Billion |
| 2022 | 12.99% | 23.55% | 0.39x | 1.42x | ₩123.90 Billion |
| 2023 | 3.15% | 24.61% | 0.11x | 1.17x | ₩-1.16 Trillion |
| 2024 | 2.42% | 11.88% | 0.17x | 1.21x | ₩-1.32 Trillion |
Industry Comparison
This section compares Celltrion Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $194,254,336,787
- Average return on equity (ROE) among peers: -1.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celltrion Inc (068270) | ₩16.84 Trillion | 9.04% | 0.25x | $19.24 Billion |
| ORIENTBIO Inc. (002630) | $65.49 Billion | 6.21% | 0.30x | $28.89 Million |
| Green Cross (005250) | $236.96 Billion | 2.17% | 6.45x | $218.29 Million |
| Green Cross Holdings Preference Shares (005257) | $1.18 Trillion | 4.81% | 0.52x | $397.12 Million |
| Pharmicell (005690) | $82.82 Billion | -21.94% | 0.22x | $396.23 Million |
| GeneOne Life Science Inc (011000) | $35.85 Billion | -43.51% | 0.83x | $40.52 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $36.31 Billion | 4.18% | 0.71x | $11.78 Million |
| Seoulin Bioscience Co.Ltd (038070) | $48.60 Billion | 8.38% | 0.37x | $25.41 Million |
| Hyundai Bioscience Co. Ltd (048410) | $14.17 Billion | 0.00% | 1.15x | $752.29 Million |
| iNtRON Biotechnology Inc (048530) | $101.35 Billion | 9.60% | 0.51x | $63.23 Million |
| Synergy Innovation Co. Ltd (048870) | $139.91 Billion | 11.53% | 0.63x | $75.10 Million |